Activated AKT inturn phosphorylates the downstream molecules PDK1 and mTOR, which on further activates the transcription factors responsible for the cell survival, growth and proliferation.37 AKT inhibitor GDC 0068 and mTOR inhibitor RAD‐001 are currently used to treat lung cancer patients in phase I trial,38 which has severe side effects. This evidence concerns the gene AKT1 and lung carcinoma.